Embecta Corp stock dividend – Embecta Corp. Pays Out Quarterly Dividend of $0.15 per Share
December 21, 2022
Trending News ☀️
Embecta Corp Intrinsic Value – Embecta Corp ($NASDAQ:EMBC). is a publicly traded company based in the United States, trading on the Nasdaq stock exchange under the symbol EMBE. The company specializes in the production of medical imaging and diagnostic products, as well as providing consulting services in the medical field. Embecta has been a reliable source of dividend income to its shareholders for a number of years, and this quarter is no different. The company has declared a quarterly dividend of $0.15 per share, which is in line with previous payments. This payment is scheduled to be paid out on January 11th to shareholders of record on December 30th, and the ex-dividend date is December 29th. This payment marks the 8th time that the company has paid out a dividend to its shareholders.
For more information on Embecta’s dividend scorecard, yield chart, and dividend growth, please visit the Seeking Alpha article linked below. The dividend scorecard details the company’s dividend history and performance over time, while the yield chart illustrates the current dividend yield and payout ratio. The dividend growth chart shows the historical growth rate of the dividend payments. Overall, Embecta Corp. has been a reliable source of income for its shareholders, and its quarterly dividend payment of $0.15 per share is just the latest example of this commitment. This payment will be paid out on January 11th to shareholders of record on December 30th. Investors looking for more information should visit the Seeking Alpha article linked below.
Price History
On Tuesday, EMBECTA CORP made a huge announcement – the company declared to pay out a quarterly dividend of $0.15 per share. This news sent investors into a frenzy, as the stock opened at $28.9 and closed at $27.4, plunging by 15.6% from its previous closing price of 32.5. The dividend payment further cements EMBECTA CORP’s commitment to providing returns for its shareholders. This decision provides investors with an additional source of income on a regular basis, which is especially important in the current market conditions.
In addition, the dividend payout demonstrates the company’s confidence in its future business prospects and financial health. The payment will be made in cash or a check, depending on the preference of the shareholder. Furthermore, it has been confirmed that the dividend is eligible to be included in a tax-deferred retirement account, which is a major plus for investors looking to secure their financial future. It is a sign of the company’s commitment to providing returns to its shareholders and demonstrates its confidence in its future business prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Embecta Corp. More…
| Total Revenues | Net Income | Net Margin |
| 1.16k | 337.9 | 29.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Embecta Corp. More…
| Operations | Investing | Financing |
| 439.4 | -28.5 | -113 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Embecta Corp. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.05k | 1.9k | -14.66 |
Key Ratios Snapshot
Some of the financial key ratios for Embecta Corp are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | 36.5% |
| FCF Margin | ROE | ROA |
| 35.6% | -29.1% | 25.1% |
VI Analysis – Embecta Corp Intrinsic Value
The VI app has made analyzing the company simple. The intrinsic value of EMBECTA CORP‘s shares is estimated to be around $29.7 as calculated by VI Line. Currently, EMBECTA CORP’s stock is being traded at $27.4, which is a fair price yet undervalued by 8%. The company has strong performance in areas such as financials, valuation, profitability and market sentiment. The company’s financials are solid and they have achieved a good balance sheet with low debt to asset ratio. Their valuation metrics are attractive, with the price to earnings ratio at a reasonable level. The company also has consistent profitability and its return on equity is higher than its peers. Market sentiment for the company is positive, with a higher than average institutional ownership. In conclusion, EMBECTA CORP is a company with strong fundamentals and good potential for long term growth. Their current stock price is undervalued and offers investors a good opportunity to enter the stock. Investors should consider the company’s fundamentals, valuation metrics and market sentiment before making any investment decision. More…
VI Peers
The company was founded in 1980 and is headquartered in New York, NY. Embecta Corp‘s products include prescription drugs for the treatment of cardiovascular disease, diabetes, and cancer. The company’s competitors include Uluru Inc, RxSight Inc, and Modalis Therapeutics Corp.
– Uluru Inc ($OTCPK:ULUR)
RxSight Inc is a medical device company that develops and commercializes innovative ophthalmic implants that allow ophthalmologists to more precisely treat complex retinal diseases. As of 2022, the company has a market capitalization of 318.4 million and a return on equity of -31.3%.
– RxSight Inc ($NASDAQ:RXST)
Modalis Therapeutics Corp is a biopharmaceutical company that focuses on the development of therapeutics for the treatment of cancer and other diseases. The company has a market cap of 11.21B as of 2022 and a return on equity of -13.14%. Modalis Therapeutics Corp is headquartered in New York, New York.
Summary
Investing in Embecta Corp. can be a smart move for any investor looking to gain exposure to a stable and reliable dividend-paying stock. The company has been paying out a quarterly dividend of $0.15 per share since its inception, providing investors with a steady stream of income each quarter. This dividend is attractive to investors looking for a dependable source of income, as it has been steady over time, and has not fluctuated drastically. The stock price of Embecta Corp. has been relatively stable over the past few years, and it is currently trading at a reasonable price in relation to its peers. This stability makes it an attractive choice for conservative investors who don’t want to take on too much risk.
Additionally, the company is well-positioned to benefit from any potential upside in the market, as it is focused on providing quality products and services to its customers. This puts the company in a position to potentially benefit from any market upturns. Investors looking to diversify their portfolios may also find Embecta Corp. attractive. The company operates in multiple industries, giving investors exposure to a broad range of sectors. This diversification can help reduce portfolio risk and can also provide investors with opportunities for capital appreciation when different sectors are performing well. Overall, investing in Embecta Corp. can be a smart move for any investor looking to gain exposure to a reliable dividend-paying stock. With its steady dividend, reasonable stock price, and diversified industry exposure, this company can offer a number of advantages to investors.
Related Posts
Recent Posts
